Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Community-based participatory research (CBPR) offers effective, flexible approaches well suited to conduct health research with underrepresented populations that can be tailored to unique social, cultural, and geographic contexts.
Why it matters
This paper describes a community-based participatory research model for dementia research in rural northern Minnesota, built on partnerships with community organizations, healthcare providers, and academics. The model is presented as a framework for recruiting participants across rural regions, and the authors state it may be applicable to other rural regions beyond the upper Midwest.
-
This approach predicts clinical progression (2-year Clinical Dementia Rating Sum of Boxes change > 1) with an area under the curve of 0.836.
Why it matters
This screening approach uses machine learning to predict which patients will progress, and could cut the number of subjects needed by 55% and shorten recruitment by 13 months. It is a trial-design tool, not a treatment, so it may speed up testing of therapies rather than cure or prevent Alzheimer's itself.
-
CAA may be encountered as an isolated pathology or with Alzheimer disease and has been demonstrated to be associated with an increased risk of seizures.
Why it matters
This review reports that cerebral amyloid angiopathy is associated with an increased risk of seizures, but notes that most prior studies were case reports or small series and that long-term prospective or retrospective studies on seizures and outcomes in this condition are lacking. It found that status epilepticus and drug resistance were infrequent in the cases examined.
-
33/100
Conventional dementia screening tools, whether paper tests or static artificial intelligence (AI) models, capture only a snapshot of cognition and need to be adminstered periodically.
Why it matters
This paper proposes using 'agentic AI' systems built on large language models to make dementia cognitive screening more adaptive and explainable. It is a proposed roadmap, not a tested treatment, cure, or prevention for Alzheimer's disease.
-
Access is controlled through both technical and procedural methods and overseen by an external advisory committee Results Expo‐AD is currently storing personal identifiers and neuropathology data of 10,875 brain donors acquired from 22 participating brain banks and the National Alzheimer’s Coordinating Center.
Why it matters
This describes a research infrastructure that stores personal identifiers and neuropathology data from 10,875 brain donors across 22 brain banks and the National Alzheimer's Coordinating Center. It does not report any findings about treating, curing, or preventing Alzheimer's disease.
-
The model outperformed conventional ones, with an out-of-bag R2 of 74.8%.
Why it matters
This county-level analysis found that green space, lack of leisure-time physical activity, binge drinking and mobile homes were among the factors most linked to Alzheimer's disease dementia prevalence across U.S. counties. It does not test a treatment or cure, but it suggests that county-specific efforts to improve green space, reduce air pollution and support physical activity could be studied for their impact on dementia prevalence.
-
Using a fit‐for‐purpose validated algorithm, the 2019 annual prevalence and incidence of ADRD in the Medicare population aged 65+ with Part D enrollment was estimated to be 18% and 5.8% respectively.
Why it matters
This study used a validated claims algorithm to estimate 2019 prevalence and incidence of Alzheimer's disease and related dementias in the US Medicare population. It is a methods study for measuring how common dementia is, not a study of treating, curing or preventing it.
-
It has been increasingly recognized that the pathological progress of Alzheimer´s disease (AD) is connected to metabolic function and inflammation.
Why it matters
This study explored associations between insulin-degrading enzyme, total tau and cytokines in plasma from 18 patients with Alzheimer's disease and 6 non-demented controls. It is a small study of biological associations, not about treating, curing or preventing the disease.
-
Høilund-Carlsen and colleagues raise important issues related to amyloid PET, diagnosis of Alzheimer disease, and recently approved antiamyloid treatment aducanumab.
Why it matters
This commentary discusses issues raised about amyloid PET, the diagnosis of Alzheimer disease and the recently approved antiamyloid treatment aducanumab. It suggests new developments may point toward presymptomatic detection and the development of effective prevention and therapy.
-
A third of Medicare beneficiaries are enrolled in Medicare Advantage (MA); however, little is known about MA beneficiaries diagnosed with Alzheimer’s disease and related dementias (AD/ADRD).
Why it matters
This study calculated how common diagnosed Alzheimer's disease and related dementias were in three Medicare Advantage plans in 2014 and 2016, finding prevalence was lower than rates reported in traditional Medicare. It is about diagnosis documentation, not about treating, curing, or preventing Alzheimer's disease.
-
Cortical posterior hypometabolism on PET imaging with 18 F-FDG (FDG-PET), and altered levels of Aß 1-42 peptide, total Tau (tTau) and phosphorylated Tau (pTau) proteins in cerebrospinal fluid (CSF) are established diagnostic biomarkers in Alzheimer's disease (AD).
Why it matters
This retrospective review of 120 patients with cognitive impairment assessed how well brain FDG-PET and cerebrospinal fluid biomarkers agree when diagnosing Alzheimer's disease. It is about diagnostic agreement between tests, not about treating, curing or preventing the disease.
-
Alzheimer disease (AD) is a most common form of dementia and eventually causes impairments of learning ability and memory function.
Why it matters
In rats with streptozotocin-induced Alzheimer-like disease, treadmill exercise improved spatial learning and short-term memory and reduced markers of apoptosis and glial activation. This is an animal study, so it does not show that exercise produces the same benefits in people with Alzheimer disease.
-
We determined that several iterations of the discriminant analysis improved the classification of subjects into the AβL and AβH groups.
Why it matters
This methods study found that a specific brain region combining the posterior cingulate cortex/precuneus and medial frontal cortex best separated people into low and high amyloid groups on amyloid PET. It concerns how to classify scans and does not test a treatment or prevention for Alzheimer disease.
-
Mutations in the presenilin 1 (PS1) gene (PSEN1) are associated with familial Alzheimer disease (FAD).
Why it matters
This reports a single 50-year-old patient with early-onset familial Alzheimer disease who was found to carry a new presenilin 1 mutation. It adds to knowledge about genetic causes of the rare inherited form of the disease, but does not test or suggest any treatment.
-
33/100
In recent studies, patients diagnosed with Alzheimer's disease (AD) showed significantly elevated CSF levels of tau protein.
Why it matters
This study measured cerebrospinal fluid total tau protein in patients with Alzheimer's disease, aging-associated cognitive decline, and healthy controls. It concerns diagnosis and does not report any treatment, cure, or prevention.
-
Economic assessments of health and healthcare have become an integral part of policy decisions in the last decade.
Why it matters
This review found that the economic costs of Alzheimer disease care are highly variable, largely due to non-standardised methods and geographical differences in care patterns, and that there are relatively few cost-effectiveness studies of interventions. It does not test a dementia treatment or cure.
-
The objective of this prospective study was to evaluate the cost of Alzheimer disease (AD) in Israel.
Why it matters
This study estimated the economic cost of caring for people with Alzheimer's disease in Israel, finding that most services were paid out of pocket. It does not test any treatment, cure, or prevention, and it suggests that efforts to delay deterioration and institutionalization could affect future costs.
-
The measurement of CSF specimens from Netherlands Brain Bank showed that the levels of total tau and p-tau in CSF specimens of AD patients were significantly higher than those in CSF of patients with VD and non-dementia neurological disorders, and of age-matched non-
Why it matters
In this study, levels of total tau and p-tau in cerebrospinal fluid were significantly higher in Alzheimer's disease patients than in those with vascular dementia, other non-dementia neurological disorders, and age-matched controls. This supports the use of these cerebrospinal fluid markers to help distinguish Alzheimer's disease from other conditions, though the study does not address treatment or prevention.
-
We found that an ecological measure of socio-economic deprivation was related to VaD but not to AD PSD.
Why it matters
This study examined factors such as occupation, paternal age and area of residence in people with presenile Alzheimer's disease in Scotland. It does not test any treatment, cure or prevention, and the findings are from an older ecological analysis rather than a trial of any intervention.
-
Two groups of subjects, 14 young (ages 20 to 31 years) and 14 adults (ages 32 to 54 years), both groups with Down Syndrome, were examined on a matching and naming olfactory task.
Why it matters
Adults with Down syndrome scored worse than younger people with Down syndrome on two olfactory tasks, and the authors suggest these tasks could be a useful noninvasive diagnostic method. This is about diagnosis and does not test any treatment, cure, or prevention.
-
Platelets are the main source of 5-hydroxytryptamine (5-HT) and amyloid precursor protein (APP) found in plasma.
Why it matters
Platelets were elevated and their ability to take up and accumulate serotonin was reduced in Alzheimer's disease patients compared with healthy individuals. The authors suggest platelets may provide a systemic marker of Alzheimer's disease, which is about diagnosis rather than treatment.
-
The brains of individuals with Down's syndrome in their 40's and 50's begin to develop changes that are otherwise seen only in patients with Alzheimer disease.
Why it matters
This paper describes how the brains of people with Down syndrome in their 40s and 50s develop neurofibrillary tangles and beta/A4 amyloid deposits in a predictable pattern, with certain neurons such as those in layer II of entorhinal cortex and the CA1/subiculum being affected first. It proposes that the extra copy of the amyloid precursor protein gene on chromosome 21 may explain the predisposition, but it reports no treatment or cure.
-
Studies were undertaken to assess the extent to which messenger RNA prepared from the postmortem Alzheimer's disease (AD) brain can be used for the successful preparation of a recombinant cDNA library.
Why it matters
The researchers showed they could build a cDNA library from postmortem Alzheimer brain tissue and identify a GFAP gene copy in it. This is a laboratory methods study from 1988 and provides no treatment, cure, or prevention for Alzheimer's disease.
-
In AβO-injected mice, AR, particularly at 200 mg/kg, attenuated memory deficits, reduced hippocampal neuronal degeneration, preserved synaptic protein immunoreactivity and increased markers of hippocampal cell proliferation and immature neurons.
Why it matters
In mice injected with amyloid-beta oligomers and in cultured cells, Alismatis Rhizoma reduced memory deficits, neuronal degeneration and synaptic loss. The authors describe this as promising preclinical evidence and call for testing in chronic and progressive Alzheimer's disease models, so it is not yet a proven treatment.
-
The recent approval of disease-modifying therapies (DMTs) for early Alzheimer's disease (AD) marks a major shift in clinical practice.
Why it matters
This Belgian expert consensus outlines a stepwise diagnostic approach for Alzheimer's disease that combines clinical assessment with biomarker confirmation using cerebrospinal fluid, amyloid-PET and emerging blood-based tests. It focuses on how to organise diagnosis and care as disease-modifying therapies arrive, and does not itself test any treatment, cure or prevention.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Autophagy in Alzheimer's disease pathogenesis: Therapeutic potential and future perspectives
- Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline
- Activation of 574 new Alzheimer’s special care unit beds in the Metropolitan City of Milan
- Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease
- Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study
- Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer's disease
- Aging and Alzheimer's disease: Comparison and associations from molecular to system level
- [Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial]
- Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study
- Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease